Background: Gastric gastrointestinal stromal tumors (GISTs) represent a subgroup of GISTs with a better prognosis than those located in other areas. In this retrospective study we performed a molecular characterization of a large series of patients with gastric GISTs in relation to clinicalepathological characteristics and prognosis. Methods: DNA was extracted from paraffin-embedded sections from 221 gastric GIST patients submitted to surgery. Exons 9, 11, 13 and 17 of KIT, exons 12 and 18 of PDGFRA and exons 11 and 15 of BRAF were analyzed by direct sequencing. Cox regression analysis adjusted for clinicalepathological factors was performed to evaluate KIT and PDGFRA mutations in relation to the composite endpoint of relapse or death. Results: KIT and PDGFRA mutations were observed in 119 (53.8%) and 56 (25.3%) patients, respectively, whereas 46 (20.8%) patients had wild type (wt) disease. Univariable analyses showed that a high Miettinen risk category and the presence of ulceration and KIT deletions
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and can develop in any part of this area; 60e70% of clinically manifest tumors arise in the stomach and 20e30% in the small intestine, but a small percentage also occurs in the rectum, colon, esophagus or omentum.
1e3 About 70e80% of GISTs harbor a KIT gene mutation in exons 11 (about 60% of cases) and 9 (7e10%) and, less frequently, in exons 13 and 17. 4e6 About 20e30% of KIT wild type (wt) GISTs show mutations in the plateletderived growth factor receptor alpha (PDGFRA) gene, in particular in exons 12, 14 and 18, 6,7 while a lower percentage (4e13%) have BRAF mutations. 8e10 Gastric GISTs represent a subgroup of GISTs with a favorable prognosis and are characterized by a relatively higher fraction of cases with an epithelioid or mixed epithelioid/spindle morphology, a higher frequency of PDGFRA mutations and a lower frequency of KIT alterations, a lower mitotic index and overall lower mortality than other GISTs. 11e14 Whilst the predictive role of KIT and PDGFRA mutations in relation to response to imatinib is well known, 15e17 the prognostic significance of these mutations and of the type of mutation has yet to be defined. Some studies have shown that gastric GISTs with exon 11 deletions have a worse outcome than those with single nucleotide substitutions at the same exon.
18e20 PDGFRA exon 18 mutations have also been associated with a lower risk of metastasis and a better prognosis. 12, 18 Other studies have demonstrated that, in addition to different exons, the type of mutation and several codons affected by mutations may have different prognostic implications. In particular, KIT exon 11 deletions are associated with a risk of metastasis, while those involving codons 557e558 indicate a higher risk of progression. 21e25 Conversely, single KIT exon 11 substitutions have been correlated with longer relapse-free and overall survival. 15, 21, 23, 25, 26 Moreover, KIT exon 9 duplications, which occur mainly in intestinal tumors, have been associated with aggressive behavior. 21, 25 A number of studies have also analyzed BRAF gene alterations in GISTs, reporting a mutation frequency of about 4e13%.
8e10 A predominant small intestinal location of GISTs with BRAF V600E has been observed, followed by a location in the stomach. 8 BRAF mutations are not per se indicative of malignancy in that they have not been found to show a significant correlation with prognosis. 9 However, a recent study in which GIST patients were divided into 3 prognostic groups on the basis of type of mutation found that BRAF mutations were associated with the group with the best prognosis, suggesting a positive prognostic effect of this alteration. 27 The main aim of our retrospective study was to assess KIT, PDGFRA and BRAF mutations in a large series of patients with gastric GISTs recruited by member centers of the Italian Research Group of Gastric Cancer (GIRCG). We analyzed different gene mutations and types of mutation in relation to the clinicalepathological characteristics of patients to see whether this information could be used to improve the clinical management of the disease.
Materials and methods

Case series
We retrospectively analyzed a cohort of 221 patients with gastric GISTs submitted to surgical resection between March 1985 and December 2012. All cases were recruited from 8 member centers of the Italian Gastric Cancer Research Group (GIRCG). Information on clinicalepathological data such as tumor size, mitosis, presence of ulceration, necrosis, atypia and type of cellularity was collected by reviewing all available medical and histopathological records archived in GIRCG centers. The study was approved by the Local Ethics Committee of each center.
Histopathological variables analyzed for each tumor were as follows: size, mitotic count per 50 high-power fields (HPF), cell type, presence or absence of ulceration, necrosis and nuclear atypia, and pattern of KIT and MIB1 immunostaining. Immunohistochemical staining was performed using the following primary antibodies: KIT (CD117 antigen, Dako Corporation, Carpenteria, CA, USA) and Ki67 (MIB1, Dako Corporation).
On the basis of the Miettinen risk score, GISTs were stratified as no-, very low-, low-, intermediate-and highrisk tumors. 2 
Molecular analysis
Formalin-fixed-paraffin-embedded (FFPE) tumor samples were used for molecular analysis. For each sample, areas containing at least 50% of tumor cells were selected in hematoxylin-eosin-stained sections, macrodissected in 5-mM sections and collected in specific tubes for DNA extraction. Tumor cells were lysed overnight at 56 C in 50 mM of KCl, 10 mM of TriseHCl pH 8.0, 2.5 mM of MgCl 2 and Tween-20 (0.45%) in the presence of 1.25 mg/ml of proteinase K. Proteinase K was inactivated at 95 C for 10 min and samples were centrifuged twice at 6000 rpm to eliminate debris. DNA quantity and quality were assessed by Nanodrop (Celbio, Milan, Italy). Fifty nanograms of DNA were used for PCR amplification.
KIT exons 9, 11, 13 and 17 and PDGFRA exons 12 and 18 were analyzed by direct sequencing using 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Primer sequences and localizations are reported in Table  S1 and Fig. S1 , respectively.
BRAF exons 11 and 15 were analyzed by pyrosequencing using an anti-EGFR MoAb response (BRAF-status) kit (Diatech, Jesi, Ancona, Italy), according to the manufacturer's instructions. Reactions were run on a PyroMark Q96 ID (Qiagen, Milan, Italy).
Statistical analysis
The primary endpoint of the study was recurrence-free survival (RFS), defined as the time from the date of surgery to the date of tumor recurrence or death resulting from any cause. In patients who did not relapse or died, the end date was the last follow up. Descriptive statistics were reported as frequencies and percentages for categorical variables and as mean AE standard deviation (SD) for continuous variables. The association between types of mutation and demographic (age and gender) and clinicalepathological features was assessed by the t-test and Chi-square test or Fisher's Exact test, as appropriate. Survival curves were estimated using the KaplaneMeier method, while the statistical significance of the differences between curves was assessed using the log-rank test. The prognostic impact of specific variables on survival was analyzed by univariable and multivariable Cox proportional hazards models. Results are reported as Hazard Ratios (HRs) and 95% confidence intervals (95% CI). The proportional hazards assumption was checked by the Schoenfeld residuals-based test. For some variables, levels were combined due to the low number of observations.
The choice of variables to include in the multiple Cox regression model was based on stepwise selection methods and careful clinical judgment. The Akaike Information Criterion was used to select the final multiple regression models. The two multivariable Cox regression models included the Miettinen risk score as adjustment factor and the different types of mutation or the exon 11 KIT mutations. Statistical interactions between demographic, clinicalepathological variables and type of mutation were explored. The prognostic role of the type of mutation was also assessed within treatment groups.
All statistical analyses were carried out using STATA 10.1 statistical software (StataCorp, College Station, TX, USA). A two-sided p-value < 0.05 was deemed statistically significant for all the analyses.
Results
Patient characteristics
Information available on the clinicalepathological characteristics of the of 221 gastric GIST patients is reported in Table 1 . Mean age at the time of surgery was 65 AE 13 years. One hundred and twenty patients (54.3%) were male and 101 (45.7%) were female. One hundred and sixty-two (85.7%) did not receive any type of treatment, 27 (14.3%) underwent neoadjuvant or adjuvant therapy and no information about treatment was available for 32 patients. Treated patients were similar to non treated patients as regards demographic variables but had a more serious clinical and histological profile (Table S2 ). In particular, they showed significantly higher tumor dimensions (p ¼ 0.001) and number of mitoses (p < 0.001). Consequently, the Miettinen risk score was substantially higher in treated patients and necrosis and atypia were more frequent, albeit not significantly, than in non treated cases (p ¼ 0.091 and p ¼ 0.074, respectively).
Genotype analysis
Overall, 119 (53.8%) patients showed KIT mutations and 56 (25.3%) had PDGFRA mutations. Forty-six (20.8%) patients had KIT and PDGFRA wt GISTs. No BRAF mutations were detected. One hundred and sixteen of the 119 KITmutated patients showed alterations in exon 11:47 point mutations, 43 deletions and 26 insertions. Three patients had mutations in exon 9, all of which were insertions. Five of the 56 PDGFRA-mutated patients had exon 12 alterations (4 point mutations and 1 deletion), while 51 showed exon 18 mutations (44 point mutations and 7 deletions).
Association between mutations and clinicalepathological characteristics of patients
The associations between the different types of mutations and pathologic tumor features are presented in Table  S3 . The majority of KIT mutations displayed spindle morphology, while PDGFRA alterations had a mainly epithelioid phenotype (76.3% and 41.9%, respectively; p < 0.001). In general, the majority of GISTs carrying KIT or PDGFRA mutations had low mitotic activity ( 5/ 50 HPF) (85.1% and 75.2% respectively; p ¼ 0.052).
Overall, KIT-mutated patients showed worse pathological features, i.e., a higher percentage of spindle cellularity (p < 0.001), necrosis (p ¼ 0.045), and a higher Miettinen risk score (p ¼ 0.004), (Table S3) .
Survival analyses
The relationship between mutations and patient prognosis in terms of RFS (considered as a composite endpoint including recurrence or death, whichever came first) was evaluated in 190 patients for whom information on date of surgery and follow up was available. Of these, 151 (79.5%) did not receive any type of treatment after surgery, while 27 (14.2%) received adjuvant or neoadjuvant therapy. Data were missing for 12 (6.3%) patients. The median follow up of patients who remained relapse-free after the last update was 72 months. There were 23 recurrences and 34 deaths from all causes without previous relapse, of which 19 from other tumors, 10 from non-cancerrelated disease, one from old age and 4 from unknown causes. KIT mutations were detected in 100 (52.6%) of the 190 patients, while PDGFRA alterations were observed in 52 (27.4%) cases. Thirty-eight (20%) patients harbored the wt form of either gene. Three (3%) KIT mutations were exon 9 insertions, 40 (40%) were exon 11 deletions, 36 (36%) were exon 11 point mutations, and 21 (21%) were exon 11 insertions. Mutations involving codons 557, 558 or 559 were observed in 49 (49%) KIT-mutated patients. In particular, codons 557, 558 or 559 were involved in 22/36 (61%), 26/40 (65%) and 1/21 (5%) exon 11 point mutations, deletions or insertions, respectively ( Table 2) .
Among PDGFRA mutations, 5 (10%) were at codon 12 (4 point mutations and 1 deletion) and 47 (90%) were at codon 18 (40 point mutations and 7 deletions) ( Table 2) .
The association between mutation types and RFS is reported in Fig. 1 .
A significantly lower RFS was observed in patients with KIT deletions than in those with KIT and PDGFRA wt, PDGFRA-mutated, and KIT point or insertion mutations (p ¼ 0.002) (Fig. 1A) . Moreover, mutations in codons 557, 558 or 559, in particular deletions, were associated with a significantly lower RFS than wt genes or mutations in other codons (p < 0.001) (Fig. 1BeC) .
Cox univariable analyses showed that tumor dimension, number of mitoses, presence of ulceration, necrosis and a high Miettinen risk score were associated with a higher Table 1 Clinical pathological characteristics of gastric GIST patients (n ¼ 221). Table 3) .
The results from two multivariable Cox regression models are reported in Table 4 . Model 1 considers the prognostic effect of the type of mutations (KIT or PDGFRA) adjusting for the Miettinen risk score, while Model 2 focuses on the effect of the different types of exon 11 KIT mutations on prognosis, once again adjusting for the Miettinen score. After adjusting, KIT deletions remained an independent predictor of recurrence or death ( with a KIT deletion in codons 557, 558 or 559 was more than 3- Model 2) . In treated patients, the only variable associated with RFS was the Miettinen score and none of the molecular variables proved significant even after adjusting for the score (Table S5 , Models 1 and 2).
Discussion
The prediction of clinical behavior and the prognosis of patients with GISTs depend largely on classic clinicalepathological risk criteria based on tumor size, mitotic activity and localization of the primary lesion. The mutational status of KIT and PDGFRA can predict the response to treatment with tyrosine kinase inhibitors, 16, 17 but its role as a prognostic factor remains unclear. Moreover, a significant association has been found between clinicalepathological parameters and molecular alterations, which could also prove to be a prognostic factor.
In our retrospective case series of gastric GISTs, 53.9% and 25.3% of patients showed KIT and PDGFRA mutations, respectively, while 20.8% had KIT and PDGFRA wt tumors. These frequencies are lower for KIT and higher for PDGFRA than the same mutations observed in non gastric GISTs, 4, 5, 7, 10, 21, 28 in agreement with results from other studies. Miettinen et al.
14 observed a 22.6% incidence of PDGFRA mutations in a series of gastric GISTs, while Wasag et al. 29 reported that all PDGFRA mutations (25%) found in their GIST case series were observed in gastric GISTs. In Wardelmann et al.'s study, 30 all the GISTs with PDGFRA mutations (23%) were located in the stomach, whereas tumors with KIT mutations (47%) or wt status were also found in the small bowel.
It has been shown that PDGFRA mutations in GISTs are associated with a better prognosis. 7, 15, 18, 21, 31 The higher PDGFRA mutation frequency observed in gastric GISTs is in accordance with the better prognosis observed for this type of tumor. 12, 30, 32 Our study revealed the potential prognostic relevance of the type and position of KIT mutations in untreated resected gastric GISTs, in addition to classic pathological criteria such as dimension, mitosis, Miettinen risk stratification, ulceration and necrosis. Tumors with mutations (especially deletions), affecting codons 557, 558 or 559 of KIT exon 11 would appear to be a distinct subset of gastric GISTs with malignant clinical Table 3 Results from univariable analysis using the Cox proportional hazards model.
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Gender behavior. Deletions involving codons 557, 558 or 559 were associated with a higher risk of relapse or death than that of deletions with no involvement of any of these codons. Moreover, survival analysis showed that patients with these mutations had a lower RFS than those with mutations in other sites. Multiple regression analysis confirmed the independent prognostic value of this finding: adjusting for the clinical covariate of the Miettinen risk stratification system, deletions of exon 11 codons 557, 558 or 559 remained an independent predictor of risk of recurrence or death. The negative prognostic value of exon 11 mutations was significant in untreated patients but not in the smaller group receiving adjuvant or neo-adjuvant treatment. This may be attributable to the high responsiveness of KIT exon 11-mutated patients to imatinib. 15 Previous studies have reported similar results for GISTs of different sites, demonstrating that tumors with KIT exon 11 deletions are clinically more aggressive than those with exon 11 point mutations. In particular, KIT deletions affecting codons 557 or 558 have been associated with metastatic behavior, a high risk of relapse and shorter RFS and OS with respect to other KIT exon 11 mutations or deletions involving other codons. 14,19,21e25,27,31,33 The higher risk of recurrence or death in patients with GISTs showing abnormalities in exon 11 codons 557 or 558 would seem to be due to the important role of the amino acids encoded by these two codons in KIT protein function. A number of juxtamembrane residues are needed to inhibit spontaneous KIT phosphorylation. In fact, an increase in phosphorylation could be due to the removal of the side chain of codons 553, 557, 559 or 560. In particular, codon 557 encodes for a juxtamembrane residue responsible for preventing spontaneous receptor phosphorylation and activation. Trp-557-Ala leads to a substantial increase in receptor phosphorylation. Similarly, Lys-558-Pro causes spontaneous receptor phosphorylation which may be higher than stem cell factor-induced wild-type receptor phosphorylation. These mutation-induced conformational receptor changes lose their inhibitory control of the kinase activity of the ligand-unoccupied KIT receptor. Furthermore, codons 557 and/or 558 deletions may lead to a perturbation of kinase autoinhibition via the disruption of protein conformation. 23, 34 A recent study identified three molecular risk subgroups on the basis of different KIT, PDGFRA and BRAF mutations at different exons. 27 We were not able to verify this biological classification because our case series was smaller and also because some alterations were either detected in only a few patients or not at all. We did not find mutations in BRAF gene, in agreement with some studies. 28, 35 Conversely, a number of studies reported a 4e13% frequency of BRAF mutation (V600E) in KIT and PDGFRA wt GIST patients, 8, 9, 27 the majority of which were of small bowel origin, suggesting a strong predisposition for tumors arising in this part of the gastrointestinal tract. 8, 9 This may explain the absence of BRAF mutations in our case series composed entirely of gastric GISTs.
As far as we know, this is the largest study conducted to date on gastric GISTs characterized at molecular level. Its main weakness stems from its retrospective nature, with the obvious difficulty in collecting clinical information and the consequent limitation in the number of patients for whom the analysis of prognosis was possible. Moreover, despite the known disadvantages of a composite endpoint, we decided to use it in our study because of the potential underreporting of disease recurrences related to the non homogeneous availability of follow up in the different centers involved in the study. Finally, findings from the analysis of the treated group should be interpreted with caution due to the consequently smaller sample size on which estimated hazard ratios were based.
In conclusion, we found that KIT mutations, especially deletions involving exon 11 codons 557, 558 or 559, in gastric GISTs were associated with a more aggressive phenotype and a higher risk of recurrence or death. This finding underlines the need for a more specific and broader molecular analysis for GIST patients to identify those at higher risk of relapse who could benefit from adjuvant treatment with imatinib. Furthermore, our data could be used to improve the present classification system by teaming up specific molecular alterations with currently used pathological criteria.
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